Literature DB >> 9400701

Oncogenes and tumor-suppressor genes in mesothelioma--a synopsis.

J F Lechner1, J Tesfaigzi, B I Gerwin.   

Abstract

Invariably mesothelioma is diagnosed late in the development of the disease when treatment is no longer effective. Therefore, a key to reducing the mortality rate of this neoplasm is knowledge of the general sequence of genetic events between initiation of mesothelial cells and the emergence of the metastatic tumor cells. Unfortunately, relatively little is known about the early changes in the genesis of this disease. Of the known changes, the most frequent are in the tumor-suppressor genes p16INK4a and NF2 and possibly the SV40 virus large T-antigen oncogene. The molecular nature of the changes in these genes as well as other alterations are addressed in this overview.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9400701      PMCID: PMC1470150          DOI: 10.1289/ehp.97105s51061

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  81 in total

Review 1.  Genomic instability induced by ionizing radiation.

Authors:  W F Morgan; J P Day; M I Kaplan; E M McGhee; C L Limoli
Journal:  Radiat Res       Date:  1996-09       Impact factor: 2.841

Review 2.  Transcriptional control of the cell cycle.

Authors:  I Sánchez; B D Dynlacht
Journal:  Curr Opin Cell Biol       Date:  1996-06       Impact factor: 8.382

3.  Asbestos-associated chromosomal changes in human mesothelial cells.

Authors:  J F Lechner; T Tokiwa; M LaVeck; W F Benedict; S Banks-Schlegel; H Yeager; A Banerjee; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

4.  Nonrandom chromosome alterations in human malignant mesothelioma.

Authors:  N C Popescu; A P Chahinian; J A DiPaolo
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

5.  Rb and p16INK4a expression in resected non-small cell lung tumors.

Authors:  R A Kratzke; T M Greatens; J B Rubins; M A Maddaus; D E Niewoehner; G A Niehans; J Geradts
Journal:  Cancer Res       Date:  1996-08-01       Impact factor: 12.701

6.  Molecular deletion of 9p sequences in non-small cell lung cancer and malignant mesothelioma.

Authors:  R Center; R Lukeis; E Dietzsch; M Gillespie; O M Garson
Journal:  Genes Chromosomes Cancer       Date:  1993-05       Impact factor: 5.006

7.  Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma.

Authors:  W C Lee; B Balsara; Z Liu; S C Jhanwar; J R Testa
Journal:  Cancer Res       Date:  1996-10-01       Impact factor: 12.701

8.  Induction of metaphase and anaphase/telophase abnormalities by asbestos fibers in rat pleural mesothelial cells in vitro.

Authors:  M Yegles; L Saint-Etienne; A Renier; X Janson; M C Jaurand
Journal:  Am J Respir Cell Mol Biol       Date:  1993-08       Impact factor: 6.914

9.  Immunohistochemical evaluation of ras oncogene expression in pulmonary and pleural neoplasms.

Authors:  I Lee; V E Gould; J A Radosevich; A Thor; Y X Ma; J Schlom; S T Rosen
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1987

10.  High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines.

Authors:  S Ungar; A Van de Meeren; L Tammilehto; K Linnainmaa; K Mattson; B I Gerwin
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

View more
  6 in total

Review 1.  The molecular basis of asbestos induced lung injury.

Authors:  D W Kamp; S A Weitzman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

Review 2.  Cellular and molecular parameters of mesothelioma.

Authors:  Maria E Ramos-Nino; Joseph R Testa; Deborah A Altomare; Harvey I Pass; Michele Carbone; Maurizio Bocchetta; Brooke T Mossman
Journal:  J Cell Biochem       Date:  2006-07-01       Impact factor: 4.429

3.  Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.

Authors:  Gavin J Gordon; Graham N Rockwell; Roderick V Jensen; James G Rheinwald; Jonathan N Glickman; Joshua P Aronson; Brian J Pottorf; Matthew D Nitz; William G Richards; David J Sugarbaker; Raphael Bueno
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

4.  Telomerase activity in human pleural mesothelioma.

Authors:  K Dhaene; R Hübner; S Kumar-Singh; B Weyn; E Van Marck
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

5.  p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.

Authors:  J Creaney; B M McLaren; S Stevenson; A W Musk; N de Klerk; B W Robinson; R A Lake
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

Review 6.  Reactive oxygen species a double-edged sword for mesothelioma.

Authors:  Serena Benedetti; Barbara Nuvoli; Simona Catalani; Rossella Galati
Journal:  Oncotarget       Date:  2015-07-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.